Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination
| Autor: | Hayato Tanaka, Daisuke Nagasato, Shunsuke Nakakura, Toshihiko Nagasawa, Hiroyuki Wakuda, Akihiro Kurusu, Yoshinori Mitamura, Hitoshi Tabuchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Taiwan Journal of Ophthalmology, Vol 12, Iss 2, Pp 202-205 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2211-5056 2211-5072 |
| DOI: | 10.4103/tjo.tjo_24_22 |
| Popis: | In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 2: A 56-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 1: Temporal superior BRVO and secondary macular edema (ME) were observed in the patient's right eye. Her best-corrected visual acuity (BCVA) was 20/25. Case 2: Temporal inferior BRVO and secondary ME were observed in the patient's right eye. Her BCVA was 13/20. Case 1: Three doses of intravitreal ranibizumab (IVR) were administered. Case 2: Three doses of IVR were administered. Case 1: ME resolved and BCVA improved to 20/20. Case 2: ME resolved and BCVA improved to 20/20. Both the cases showed a possible association between the SARS-CoV-2 vaccination and the first onset of BRVO. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|